Home » Treatment » Mirabegron 50mg Prolonged-Release Tablets
Mirabegron 50mg Prolonged-Release Tablets
from£55.99
A selective beta-3 adrenergic agonist containing mirabegron 50mg per prolonged-release tablet
For adults with overactive bladder syndrome (urinary urgency, frequency, urge incontinence)
Dose: 50mg once daily, swallowed whole with water. Reduced to 25mg in severe renal impairment, moderate hepatic impairment, or with strong CYP3A4 inhibitors
Contraindicated in severe uncontrolled hypertension (systolic 180 or diastolic 110). Blood pressure monitoring required
Prescription-only medicine (POM). Available from Courier Pharmacy through our prescriber service
Mirabegron 50mg tablets are prolonged-release film-coated oral tablets. Each tablet contains 50mg of mirabegron.
Firstly, the prolonged-release formulation delivers mirabegron gradually over several hours. This supports once-daily dosing.
How mirabegron differs from antimuscarinics
Mirabegron is a beta-3 adrenergic agonist. Firstly, this is a completely different mechanism from antimuscarinics (solifenacin, tolterodine, oxybutynin).
Also, antimuscarinics block the receptors that trigger bladder contractions. In contrast, mirabegron activates receptors that relax the bladder during filling.
However, both mechanisms reduce urgency and frequency. They just achieve it differently.
Furthermore, mirabegron’s different mechanism means a different side-effect profile. Firstly, less dry mouth, less constipation, less cognitive impact. However, it can raise blood pressure.
The role of 50mg as the starting dose
The standard adult starting dose in the UK and EU is 50mg once daily. Firstly, this is the full therapeutic dose.
Also, unlike solifenacin (where 5mg is the starting dose and may be increased to 10mg), mirabegron patients usually start at 50mg.
However, some patients need the reduced 25mg dose. This includes severe renal impairment, moderate hepatic impairment, and combined use with strong CYP3A4 inhibitors.
Furthermore, 25mg and 50mg tablets are the same price. So prescribers use single 25mg tablets rather than half a 50mg tablet.
A once-daily prescription-only medicine
Mirabegron 50mg is a prescription-only medicine (POM). It cannot be sold over the counter.
Firstly, a UK-registered prescriber (GP, specialist, or independent pharmacist prescriber) must issue a prescription.
Also, at Courier Pharmacy, our independent prescriber can review your case, assess suitability, and issue a prescription online.
However, this is appropriate for patients with an established overactive bladder diagnosis where antimuscarinics are contraindicated, ineffective, or not tolerated (per NICE TA290).
Key features and specifications
Active ingredient: mirabegron 50mg per prolonged-release tablet
Form: prolonged-release film-coated oral tablets, usually yellow, oval, with debossed markings
Pack: usually 30 tablets (one month’s supply at once-daily dosing)
A beta-3 agonist for overactive bladder, an alternative when antimuscarinics don’t fit
Mirabegron 50mg is a prescription-only medicine (POM) for overactive bladder syndrome in adults. It reduces urinary urgency, frequency, and urge incontinence.
Firstly, mirabegron is a selective beta-3 adrenergic agonist. This is a different mechanism from antimuscarinics like solifenacin or oxybutynin.
Also, mirabegron works by relaxing the bladder muscle (detrusor) during filling. This allows the bladder to hold more urine before signalling the need to empty.
However, 50mg is the standard adult starting dose. Unlike solifenacin (which starts at 5mg and may titrate up), mirabegron patients usually start at the full dose.
Furthermore, the 25mg strength is used in specific situations. These include severe kidney impairment, moderate liver impairment, and combined use with strong CYP3A4 inhibitors.
Mirabegron’s brand name is Betmiga (Astellas Pharma). Generic mirabegron 50mg tablets contain the same active ingredient at the same dose.
Above all, mirabegron has a different side-effect profile from antimuscarinics. Firstly, it causes less dry mouth, less constipation, and less cognitive impairment.
However, mirabegron can raise blood pressure. Regular blood pressure monitoring is required, and severe uncontrolled hypertension is a contraindication.
Also, NICE TA290 recommends mirabegron only when antimuscarinics are contraindicated, ineffective, or not tolerated. This positions it as a treatment option after antimuscarinics have been considered.
At Courier Pharmacy, we can supply mirabegron 50mg through our independent prescriber service. This allows convenient supply and periodic review.
When to seek medical advice while on mirabegron
Mirabegron is generally well tolerated when prescribed appropriately. However, some symptoms need urgent medical attention.
Sudden severe headache, sudden confusion, visual disturbance, one-sided weakness, or slurred speech. Call 999 (possible severe hypertension or stroke)
Sudden swelling of the face, lips, tongue, or throat, or difficulty breathing. Call 999 (possible angioedema)
Palpitations, feeling your heart racing, chest pain, or fainting. Contact your GP or A&E
A significant rise in blood pressure readings at home (systolic ?180 or diastolic ?110), or persistently raised readings above your usual baseline
Sudden inability to pass urine, or a significantly reduced urine output (possible urinary retention)
Widespread rash, blistering, or peeling skin. Stop the tablets and seek urgent help
Symptoms of urinary tract infection: burning on passing urine, cloudy urine, fever, or lower back pain
If your overactive bladder symptoms don’t improve after 8 weeks, or worsen
If you are pregnant, breastfeeding, or planning pregnancy, discuss with your GP or prescriber before continuing
Five key takeaways
Mirabegron 50mg is a selective beta-3 adrenergic agonist for overactive bladder syndrome. It relaxes the bladder muscle, reducing urgency, frequency, and urge incontinence.
Dose: 50mg once daily as a prolonged-release tablet. Swallow whole with water. This is the standard adult starting dose.
25mg dose is used in severe renal impairment (eGFR 15-29), moderate hepatic impairment, or with strong CYP3A4 inhibitors like ketoconazole. Contraindicated if eGFR under 15 or severe hepatic impairment.
Contraindicated in severe uncontrolled hypertension (systolic ?180 or diastolic ?110). Blood pressure monitoring is required before starting and during treatment. MHRA safety alert October 2015.
Prescription-only medicine (POM). NICE TA290 positions mirabegron for patients where antimuscarinics are contraindicated, ineffective, or not tolerated. Available from Courier Pharmacy through our online prescriber service.
What is Mirabegron 50mg Prolonged-Release Tablets: overview
Where mirabegron fits in overactive bladder treatment
Overactive bladder (OAB) affects around 11-16% of adults. It includes urinary urgency, frequency, and (sometimes) urge incontinence.
Firstly, first-line treatment is behavioural: bladder training, fluid management, reducing caffeine and alcohol.
Also, medication is considered when behavioural measures alone are not enough. Antimuscarinics (solifenacin, tolterodine, oxybutynin) are usually tried first.
However, mirabegron is positioned by NICE TA290 as an option when antimuscarinics are contraindicated, ineffective, or not tolerated.
Furthermore, some patients prefer mirabegron from the start due to its different side-effect profile (less dry mouth, less constipation).
Mirabegron vs solifenacin
Solifenacin is a selective M3 antimuscarinic. Mirabegron is a beta-3 agonist. Firstly, they work through completely different mechanisms.
Also, efficacy is broadly comparable across studies. Some patients respond better to one than the other.
However, side-effect profiles differ significantly. Solifenacin causes more dry mouth, constipation, and (rarely) cognitive effects. Mirabegron can raise blood pressure.
Furthermore, for patients who cannot tolerate antimuscarinic side effects, mirabegron is often the next step. For patients with well-controlled blood pressure, either can work.
Mirabegron vs oxybutynin
Oxybutynin is an older, non-selective antimuscarinic. Firstly, it causes more antimuscarinic side effects than newer selective antimuscarinics.
Also, oxybutynin crosses the blood-brain barrier more readily. This raises the risk of confusion, especially in older adults.
However, mirabegron does not have significant CNS penetration. So mirabegron has less cognitive impact than oxybutynin.
Furthermore, for older adults or those with existing cognitive concerns, mirabegron often has a more favourable profile.
Mirabegron vs tolterodine
Tolterodine is another antimuscarinic in the same class as solifenacin. Firstly, tolterodine has broadly similar efficacy and side-effect profile to solifenacin.
Also, mirabegron’s different mechanism gives it a genuinely different side-effect profile.
However, tolterodine can be tried before mirabegron in patients who did not tolerate solifenacin. Sometimes switching within the antimuscarinic class helps.
Long-term treatment
Overactive bladder is usually a chronic condition. Firstly, most patients need long-term treatment.
Also, mirabegron has been shown to maintain efficacy for at least 12 months in long-term studies.
However, periodic review with your prescriber is important. This checks blood pressure, efficacy, and tolerability.
Furthermore, the prescriber may recommend trying to stop the medicine periodically. This checks whether the condition has changed.
Prescriber support at Courier Pharmacy
Because mirabegron is prescription-only, buying at Courier Pharmacy involves prescriber assessment. Firstly, this ensures the medicine is suitable and safe for you.
Also, our independent prescriber can review your case, discuss options, and issue a prescription online.
However, we need to check your blood pressure history and current readings. Recent kidney and liver function results may also be relevant.
Why choose Courier Pharmacy for your Mirabegron 50mg Tablets
Registered, independent, and patient-led
Courier Pharmacy is a UK-registered independent pharmacy with independent prescribers. The General Pharmaceutical Council regulates us.
Firstly, prescription-only medicines require prescriber involvement. Our online service makes this convenient.
Also, we treat every prescription request as a chance to review your care fully. This is not a simple retail transaction.
As a result, buying mirabegron from us comes with the reassurance of UK-qualified prescriber oversight.
Dr Ada Jex-Cori, our brand pharmacist
Our brand pharmacist is Dr Ada Jex-Cori. She represents the spirit of what we do. Named for Ada Lovelace, Sophia Jex-Blake, and Gerty Cori, she stands for evidence-led, unafraid-of-questions medicine. Her message is straightforward. You’re not broken. The system is. We’re here to change that.
Care that keeps showing up
Prescription medicines need ongoing review, not one-off dispensing. Firstly, we are here to answer follow-up questions if the medicine is not working as expected.
Also, if you notice side effects or your blood pressure changes, contact us. We can review your prescription, adjust the dose, or discuss options.
However, we will not dispense repeated prescriptions to someone whose condition or blood pressure has not been reviewed.
Buy Mirabegron 50mg Prolonged-Release Tablets from Courier Pharmacy
Mirabegron 50mg is a prescription-only medicine. You can request supply through courierpharmacy.co.uk with our online prescriber service.
Complete our online consultation for overactive bladder or add mirabegron to your basket if you have an existing prescription
Our independent prescriber reviews your case (including blood pressure) and may issue a prescription if suitable
Your prescription is dispensed and dispatched promptly
Follow the pack directions carefully. Monitor your blood pressure and contact us for follow-up questions
If mirabegron is not right for your situation, we will explain why. Options include an antimuscarinic (solifenacin, tolterodine), or referral back to your GP for further assessment.
Above all, we will not issue a prescription that is not clinically appropriate.
Summary
A prescription-only selective beta-3 adrenergic agonist for adult overactive bladder syndrome.
Standard adult dose: 50mg once daily. Reduced to 25mg in severe renal impairment, moderate hepatic impairment, or with strong CYP3A4 inhibitors.
Reduces urinary urgency, frequency, and urge incontinence within 8-12 weeks. Long-term efficacy maintained over 12 months.
Contraindicated in severe uncontrolled hypertension (systolic ?180 or diastolic ?110). Requires blood pressure monitoring.
NICE TA290: option when antimuscarinics are contraindicated, ineffective, or not tolerated.
Active ingredient in Mirabegron 50mg Prolonged-Release Tablets
Mirabegron 50mg per prolonged-release tablet
Mirabegron is a synthetic selective beta-3 adrenergic receptor agonist. It was first approved in Japan in 2011 and in Europe in December 2012.
Firstly, the 50mg dose is contained in a prolonged-release matrix. This gradually releases the drug over several hours.
Also, oral bioavailability is 29-35%. Peak plasma levels occur 3-4 hours after dosing. The elimination half-life is around 50 hours.
However, this long half-life supports once-daily dosing. It also means the drug takes about a week to reach steady state.
Furthermore, mirabegron is metabolised primarily by glucuronidation and amide hydrolysis, with some CYP3A4 and CYP2D6 involvement. Excretion is mainly renal (55%) and faecal (34%).
Beta-3 adrenergic receptor selectivity
Beta-3 adrenergic receptors are found predominantly on the bladder detrusor muscle. Firstly, mirabegron selectively activates these receptors.
Also, activation causes the detrusor to relax during the filling phase. This allows the bladder to hold more urine.
However, mirabegron has some effect on beta-1 and beta-2 receptors at higher doses. This can contribute to cardiovascular effects (raised heart rate, raised blood pressure).
Furthermore, mirabegron's selectivity for beta-3 over beta-1/2 receptors is the basis for its bladder-focused effect with limited cardiovascular impact at therapeutic doses.
Why prolonged-release matters
Mirabegron is formulated as a prolonged-release (also called extended-release) tablet. Firstly, this delivers the drug gradually over several hours.
Also, this reduces the peak-to-trough variation in blood levels. This supports smoother effect and better tolerability.
However, the prolonged-release formulation must be preserved. Do not crush, chew, or split the tablets.
What is Mirabegron 50mg Prolonged-Release Tablets for?
Overactive bladder syndrome
Mirabegron is licensed for the symptomatic treatment of urgency, increased urinary frequency, and/or urge incontinence in adult patients with overactive bladder syndrome (OAB).
Firstly, OAB is defined by urinary urgency, with or without urge incontinence, usually with increased frequency and nocturia.
Also, this is a common condition, affecting around 11-16% of adults. It has significant impact on quality of life.
However, OAB is often underreported. Many patients live with the symptoms without seeking treatment.
Urinary urgency
Urgency is the sudden, strong need to urinate that is difficult to defer. Firstly, this is often the most bothersome symptom of OAB.
Also, mirabegron reduces the frequency and intensity of urgency episodes by relaxing the bladder muscle during filling.
Urinary frequency
Frequency means passing urine more often than expected (usually more than 8 times per day). Firstly, mirabegron can reduce daytime frequency by allowing better bladder capacity.
Also, this can improve quality of life significantly by reducing the need for constant toilet planning.
Urge incontinence
Urge incontinence is involuntary leakage of urine preceded by urgency. Firstly, this is often the most distressing symptom.
Also, clinical trials show significant reduction in incontinence episodes with mirabegron over 12 weeks.
However, complete resolution is not guaranteed. Some patients need additional strategies (bladder training, pelvic floor exercises).
When antimuscarinics are not suitable
NICE TA290 positions mirabegron specifically for patients where antimuscarinics are contraindicated, ineffective, or not tolerated.
Firstly, antimuscarinic contraindications include narrow-angle glaucoma, urinary retention, severe GI conditions, and myasthenia gravis.
Also, common intolerance to antimuscarinics is due to dry mouth, constipation, or cognitive effects. Mirabegron avoids these.
What mirabegron isn't for
Mirabegron is not for stress incontinence (leakage on coughing, sneezing, or exertion). Stress incontinence responds to pelvic floor exercises, physiotherapy, or surgery.
Also, it is not routinely used for urinary retention or bladder outflow obstruction. Caution is required if these are present.
However, it is not for adults with severe uncontrolled hypertension. It is not for cystitis, kidney infection, or bladder stones.
How does Mirabegron 50mg Prolonged-Release Tablets work?
Beta-3 receptor activation in the bladder
The bladder detrusor muscle has beta-3 adrenergic receptors. Firstly, these are activated by noradrenaline during the storage phase of the micturition cycle.
Also, activation causes the detrusor to relax, allowing the bladder to fill without triggering the need to void.
However, in overactive bladder, this relaxation is inadequate. The bladder signals the need to void at low volumes, causing urgency and frequency.
Furthermore, mirabegron directly activates beta-3 receptors, enhancing detrusor relaxation. This increases the volume the bladder can hold before signalling.
Different mechanism from antimuscarinics
Antimuscarinics (solifenacin, tolterodine, oxybutynin) block the receptors that cause the bladder to contract. Firstly, they reduce unwanted contractions.
However, mirabegron works during the filling phase, promoting bladder relaxation rather than blocking contraction.
Also, this different approach means mirabegron doesn't cause the typical antimuscarinic side effects (dry mouth, constipation, cognitive effects).
Furthermore, the two mechanisms can complement each other. Combination therapy is possible under specialist supervision.
Blood pressure and heart rate effects
Mirabegron's selectivity for beta-3 over beta-1/2 receptors is not absolute. Firstly, some effect on other beta receptors occurs at therapeutic doses.
Also, this can cause a small rise in heart rate and blood pressure in some patients.
However, most patients experience minimal cardiovascular effects. Blood pressure monitoring identifies those who do.
Long half-life for once-daily dosing
Mirabegron has an elimination half-life of around 50 hours. Firstly, this allows once-daily dosing.
Also, steady state is reached after about a week of continuous dosing.
However, the long half-life also means that if you stop the medicine, it takes several days to clear from your system.
How to take Mirabegron 50mg Prolonged-Release Tablets
Standard adult dose
Take 1 tablet (50mg) once daily. This is the standard adult starting dose.
Also, swallow the tablet whole with a glass of water. Take with or without food.
However, take at approximately the same time each day. This helps you remember and maintains steady blood levels.
Do not crush, chew, or split the tablets
Above all, mirabegron tablets are prolonged-release. Firstly, they are designed to release the drug gradually over several hours.
However, crushing, chewing, or splitting destroys this controlled-release mechanism. This can cause a sudden high dose all at once.
Also, if you cannot swallow tablets whole, discuss options with your prescriber. Do not modify the tablets yourself.
Reduced dose (25mg) situations
Some patients need the reduced 25mg dose instead of 50mg. Firstly, this includes severe renal impairment (eGFR 15-29 mL/min/1.73m²).
Furthermore, combined use with strong CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir, clarithromycin) requires 25mg.
However, mirabegron is not recommended in severe renal impairment with eGFR under 15, or in severe hepatic impairment. In these cases, alternative treatment is needed.
How quickly it works
Symptom improvement is usually seen within the first 8 weeks of treatment. Firstly, some patients notice improvement earlier.
Also, the full effect stabilises over 12 weeks. Long-term studies show maintained efficacy over 12 months.
However, if there is no improvement after 8 weeks at the correct dose, discuss with your prescriber. A different medicine may fit better.
Blood pressure monitoring
Blood pressure should be measured before starting mirabegron. Firstly, this establishes your baseline.
Also, regular monitoring during treatment is required. This is particularly important in patients with pre-existing hypertension.
However, home blood pressure monitoring is a simple way to keep track. Report significantly raised readings to your prescriber promptly.
Missed doses
If you miss a dose, take it as soon as you remember on the same day. However, if it is nearly time for your next dose, skip the missed one.
Also, do not take a double dose to make up for a forgotten one.
Stopping treatment
Mirabegron can be stopped without a taper. Firstly, there is no withdrawal syndrome.
However, symptoms of overactive bladder are likely to return once the drug clears from your system. Discuss with your prescriber before stopping.
Also, mirabegron's long half-life (around 50 hours) means the drug takes several days to fully clear.
Combination with antimuscarinics
Mirabegron can sometimes be combined with an antimuscarinic (like solifenacin) for patients who don't respond adequately to either alone.
However, this combination is usually initiated under specialist supervision. It raises the risk of side effects, particularly urinary retention.
Also, do not add another OAB medicine to mirabegron without prescriber advice.
Warnings and precautions for Mirabegron 50mg Prolonged-Release Tablets
MHRA safety alert October 2015: severe hypertension
Above all, the MHRA issued a safety alert in October 2015. It highlighted the risk of severe hypertension with mirabegron.
Firstly, cases of severe hypertension have been reported, including hypertensive crisis with cerebrovascular or cardiac events (transient ischaemic attack or stroke).
Also, mirabegron is now contraindicated in severe uncontrolled hypertension (systolic ?180 or diastolic ?110).
However, blood pressure should be measured before starting and monitored regularly during treatment. This is particularly important in patients with pre-existing hypertension.
Severe uncontrolled hypertension (contraindicated)
Contraindicated in severe uncontrolled hypertension (systolic blood pressure ?180 mmHg or diastolic ?110 mmHg).
Also, caution is required in stage 2 hypertension (systolic ?160 or diastolic ?100).
However, well-controlled hypertension is not a contraindication. Regular BP monitoring is still important.
Severe renal impairment (dose reduction or avoidance)
In severe renal impairment (eGFR 15-29 mL/min/1.73m²), the dose is reduced to 25mg once daily.
However, mirabegron is not recommended if eGFR is under 15 mL/min/1.73m² (end-stage renal disease).
Hepatic impairment (dose reduction or contraindication)
In moderate hepatic impairment (Child-Pugh score 7-9), the dose is reduced to 25mg once daily.
However, mirabegron is not recommended in severe hepatic impairment.
Bladder outflow obstruction (caution)
Use with caution in patients with clinically significant bladder outflow obstruction (e.g. large prostate).
Firstly, mirabegron can raise the risk of urinary retention in these patients.
However, discuss with the prescriber before starting if you have known bladder outflow obstruction.
Combination with antimuscarinics (caution)
Caution when mirabegron is combined with antimuscarinics for OAB. Firstly, this raises the risk of urinary retention.
Also, patients with bladder outflow obstruction and those taking antimuscarinics are at higher risk.
However, combination therapy is sometimes appropriate under specialist supervision.
QT prolongation (caution)
Mirabegron at therapeutic doses has not shown clinically relevant QT prolongation. However, patients with known QT prolongation history were excluded from studies.
Firstly, caution is required if you have congenital or acquired QT prolongation, or take other QT-prolonging medicines.
Angioedema
Angioedema (swelling of face, lips, tongue, or larynx) has been reported. Firstly, it can occur after the first dose.
However, if you develop these symptoms, stop the tablets immediately and seek urgent medical help. Call 999 for severe symptoms.
Elderly patients
Older adults can generally use mirabegron. Firstly, no specific dose adjustment is required for age alone.
However, older adults are more likely to have renal impairment or take other medicines. These may require the reduced 25mg dose.
Pregnancy (not recommended)
Mirabegron is not recommended during pregnancy or in women of childbearing potential not using contraception. Firstly, animal studies have shown reproductive toxicity.
However, if you become pregnant or plan pregnancy while on mirabegron, discuss with your prescriber promptly.
Breastfeeding (not recommended)
Mirabegron should not be used while breastfeeding. Firstly, it is present in animal milk.
However, discuss with your prescriber about whether to stop breastfeeding or stop mirabegron.
Driving and machinery
Mirabegron is unlikely to affect the ability to drive or use machinery. Firstly, dizziness and blurred vision are less common than with antimuscarinics.
However, if you notice any effect, do not drive until it resolves.
Do not crush, chew, or split
The prolonged-release tablets must be swallowed whole. Firstly, crushing, chewing, or splitting destroys the controlled-release mechanism.
However, this can cause a sudden high dose all at once, raising side-effect risk.
Side effects of Mirabegron 50mg Prolonged-Release Tablets
Common (up to 1 in 10)
Urinary tract infection is common. Firstly, this reflects less complete bladder emptying in some patients.
Also, tachycardia (raised heart rate) is common. Headache and dizziness can occur.
However, nausea, constipation, and diarrhoea can occur but are less common than with antimuscarinics.
Uncommon (up to 1 in 100)
Uncommon side effects include palpitations, vaginal infection, cystitis, dyspepsia, and gastritis.
Also, urticaria (hives), rash, pruritus, and joint swelling can occur.
However, blood pressure increases (including new-onset hypertension) are recognised effects.
Rare and very rare
Rare side effects include hypertensive crisis, angioedema, urinary retention, eyelid oedema, and lip oedema.
Also, very rare side effects include Stevens-Johnson syndrome (severe skin reaction with mucous membrane involvement).
Serious side effects requiring urgent help
Above all, seek urgent medical help for signs of severe hypertension (sudden severe headache, visual disturbance, confusion) or stroke (one-sided weakness, slurred speech). Call 999.
Also, seek urgent help for angioedema, severe skin reactions, chest pain, palpitations with fainting, or complete inability to pass urine.
Comparison with antimuscarinics
Compared to antimuscarinics, mirabegron causes less dry mouth, less constipation, less blurred vision, and less cognitive impact.
However, mirabegron adds cardiovascular risks (raised blood pressure, raised heart rate) that antimuscarinics don't cause.
Furthermore, UTI is more commonly reported with mirabegron than with some antimuscarinics.
Drug interactions with Mirabegron 50mg Prolonged-Release Tablets
Strong CYP3A4 inhibitors
Strong CYP3A4 inhibitors raise mirabegron blood levels. Firstly, examples include ketoconazole, itraconazole, ritonavir, and clarithromycin.
Also, when combined with these, the mirabegron dose is reduced to 25mg once daily.
However, in patients with mild-to-moderate renal impairment or mild hepatic impairment already on these inhibitors, 25mg dose is recommended.
Digoxin
Mirabegron can raise digoxin blood levels. Firstly, the lowest digoxin dose should be prescribed initially.
Also, digoxin serum levels should be monitored and used to adjust the dose.
CYP2D6 substrates with narrow therapeutic index
Mirabegron is a moderate CYP2D6 inhibitor. Firstly, this can raise blood levels of CYP2D6 substrates.
Also, examples include metoprolol, propafenone, flecainide, some antidepressants (tricyclics, some SSRIs), and some antipsychotics.
However, caution and dose adjustment may be required for narrow-therapeutic-index CYP2D6 substrates.
Warfarin
Mirabegron has shown modest effects on warfarin pharmacokinetics. Firstly, monitoring is prudent when starting or stopping mirabegron in patients on warfarin.
Antimuscarinic medicines for OAB (Over active bladder)
Combination with antimuscarinics (solifenacin, tolterodine, oxybutynin, trospium, darifenacin, fesoterodine) raises the risk of urinary retention.
However, this combination is sometimes appropriate under specialist supervision.
QT-prolonging medicines
Use caution with medicines known to prolong the QT interval. Firstly, examples include some antibiotics (macrolides, fluoroquinolones), antiarrhythmics (amiodarone, sotalol), and some antipsychotics.
However, discuss with your prescriber if you take any of these.
Antihypertensives
Since mirabegron can raise blood pressure, adjustment of antihypertensive therapy may be needed. Firstly, this is uncommon but should be considered.
However, if you are on antihypertensives, your prescriber may want to monitor blood pressure more closely after starting mirabegron.
Alcohol
Alcohol is not directly contraindicated. However, alcohol can worsen bladder symptoms independently and can affect blood pressure.
Frequently asked questions about Mirabegron 50mg Prolonged-Release Tablets
How quickly does mirabegron work?
Symptom improvement is usually seen within the first 8 weeks. Also, the full effect stabilises over 12 weeks.
However, if there is no improvement after 8 weeks, discuss with your prescriber.
Can I take mirabegron with food?
Yes. Mirabegron can be taken with or without food.
However, take at approximately the same time each day for consistency.
Can I split, crush, or chew the tablets?
No. Above all, mirabegron tablets are prolonged-release. Firstly, they must be swallowed whole with a glass of water.
However, if you cannot swallow tablets whole, discuss options with your prescriber. Do not modify the tablets yourself.
Do I need to monitor my blood pressure?
Yes. Blood pressure should be measured before starting mirabegron. Firstly, regular monitoring during treatment is required.
Also, home blood pressure monitoring is a simple way to keep track.
However, report significantly raised readings to your prescriber promptly.
Will mirabegron give me dry mouth like solifenacin?
Much less likely. Firstly, mirabegron does not block muscarinic receptors, so dry mouth is uncommon.
Also, this is one of the main reasons some patients prefer mirabegron over antimuscarinics.
Will mirabegron cause constipation?
Less likely than with antimuscarinics. Firstly, mirabegron does not have the same gut motility effects.
However, constipation can occasionally occur. Report it to your prescriber if it is troublesome.
Can I drink alcohol on mirabegron?
Alcohol is not directly contraindicated. However, alcohol can worsen bladder symptoms independently and can affect blood pressure.
Also, moderate consumption is usually acceptable.
Can I drive on mirabegron?
Yes, generally. Mirabegron is unlikely to affect driving ability.
However, if you notice any effect (dizziness, blurred vision), do not drive until it resolves.
Can I stop mirabegron suddenly?
Yes. Mirabegron can be stopped without a taper. Firstly, there is no withdrawal syndrome.
However, overactive bladder symptoms are likely to return once the drug clears (over several days).
What if I forget a dose?
Take it as soon as you remember on the same day. However, if it's nearly time for your next dose, skip the missed one.
Also, do not take a double dose to make up for a forgotten one.
Can I take mirabegron if I'm pregnant or breastfeeding?
Mirabegron is not recommended during pregnancy or breastfeeding.
However, discuss with your prescriber if you become pregnant or plan pregnancy.
Is mirabegron the same as Betmiga?
Betmiga is the original brand name for mirabegron, made by Astellas Pharma.
However, generic mirabegron 50mg prolonged-release tablets contain the same active ingredient at the same dose. They work in the same way.
Can I take mirabegron with solifenacin?
Sometimes, under specialist supervision. Firstly, the combination is used for patients who don't respond adequately to either alone.
However, this raises the risk of urinary retention. Discuss with your prescriber before combining.
Can mirabegron cause confusion?
Confusion is uncommon with mirabegron. Firstly, it has less brain penetration than antimuscarinics.
However, if you notice cognitive changes, discuss with your prescriber.
Why did NICE recommend mirabegron only after antimuscarinics?
NICE TA290 positioned mirabegron as an option when antimuscarinics are contraindicated, ineffective, or not tolerated.
Firstly, this reflects cost considerations at the time of the appraisal.
Also, antimuscarinics have longer track records and generic versions have been available for longer.
However, individual prescribers may consider mirabegron earlier if antimuscarinic contraindications or intolerance are anticipated.
How long can I take mirabegron for?
Mirabegron can be taken long-term. Firstly, clinical studies show maintained efficacy for at least 12 months.
However, periodic review with your prescriber is important. This checks blood pressure, efficacy, and tolerability.
Do I need a prescription for mirabegron from Courier Pharmacy?
Yes. Mirabegron is a prescription-only medicine (POM). Firstly, our independent prescriber can review your case and issue a prescription online if appropriate.
However, we need your blood pressure history and current readings.
Disclaimer
Disclaimer: This information is for education only and isn't a substitute for personal medical advice. Always follow the packaging directions and your prescriber's guidance, and ask your pharmacist or GP if you're unsure about your mirabegron treatment.
Medicines and Healthcare products Regulatory Agency (2024) Yellow Card reporting. Available at: https://yellowcard.mhra.gov.uk/
National Institute for Health and Care Excellence (2013) Mirabegron for treating symptoms of overactive bladder (TA290). Available at: https://www.nice.org.uk/guidance/ta290
National Institute for Health and Care Excellence (2024) Urinary incontinence and pelvic organ prolapse in women: management (NG123). Available at: https://www.nice.org.uk/guidance/ng123
National Institute for Health and Care Excellence (NICE) (no date) Lower urinary tract symptoms (LUTS) in men. NICE Clinical Knowledge Summaries. Available at: https://cks.nice.org.uk/topics/luts-in-men/ (Accessed: 5 September 2026).